Chugai Pharmaceutical (OTCMKTS:CHGCY) versus Aquestive Therapeutics (NASDAQ:AQST) Financial Survey

Aquestive Therapeutics (NASDAQ:AQST) and Chugai Pharmaceutical (OTCMKTS:CHGCY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership.

Profitability

This table compares Aquestive Therapeutics and Chugai Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-162.33%	N/A	-57.35%
Chugai Pharmaceutical	35.63%	24.91%	20.67%

Earnings & Valuation

This table compares Aquestive Therapeutics and Chugai Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$48.84 million	9.06	-$83.78 million	($0.64)	-5.50
Chugai Pharmaceutical	$8.41 billion	8.81	$2.91 billion	$0.96	23.47

Chugai Pharmaceutical has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Aquestive Therapeutics and Chugai Pharmaceutical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1	0	3	0	2.50
Chugai Pharmaceutical	0	3	1	1	2.60

Aquestive Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 148.58%. Given Aquestive Therapeutics’ higher possible upside, equities research analysts clearly believe Aquestive Therapeutics is more favorable than Chugai Pharmaceutical.

Institutional and Insider Ownership

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Chugai Pharmaceutical shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Chugai Pharmaceutical has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Summary

Chugai Pharmaceutical beats Aquestive Therapeutics on 9 of the 15 factors compared between the two stocks.

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that develops medicines and drug-delivery technologies, with a focus on treatments for central nervous system disorders and severe allergic reactions. Its PharmFilm technology enables medicines to be delivered in dissolvable oral films. The company’s products and product portfolio have included Sympazan, a clobazam oral film for seizures associated with Lennox-Gastaut syndrome, and Libervant, a diazepam buccal film for seizure clusters. Aquestive has also developed film-based medicines with commercial partners, including formulations of Suboxone and Zuplenz.

About Chugai Pharmaceutical

Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its work focuses on areas including oncology, immunology, hematology and neuroscience, and its portfolio includes biologic and antibody-based medicines as well as other pharmaceutical products. The company was established in Japan in 1925 and is headquartered in Tokyo. Since 2002, Chugai has been part of the Roche Group through a strategic alliance, while continuing to operate as a Japan-based pharmaceutical company.